Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Eye drop for treating eye dryness

A technology for eye drops and dry eyes, which is applied to medical preparations with non-active ingredients, medical preparations containing active ingredients, inorganic non-active ingredients, etc., and can solve the problems that fat-soluble eye drops cannot be completely overcome due to congenital deficiencies. Achieve the effect of protecting the corneal epithelial barrier function, good anti-inflammatory and immunosuppressive effects, and restoring quantity

Active Publication Date: 2017-08-18
EYE MEDICAL XIAMEN BIOTECHNOLOGY CO LTD
View PDF1 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Even so, compared with water-soluble drugs, the inherent deficiencies of fat-soluble eye drops still cannot be completely overcome at present

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Eye drop for treating eye dryness
  • Eye drop for treating eye dryness
  • Eye drop for treating eye dryness

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] formula:

[0023]

[0024] Preparation Process:

[0025] 1. Accurately weigh 1.00g of midazoribine, 0.03g of benzalkonium chloride, 8.30g of sodium chloride, 30mL of 0.1mol / L hydrochloric acid, add 200mL of water for injection to dissolve, stir well, and dilute to 1000mL with water for injection to obtain liquid medicine.

[0026] 2. Filter the above solution once through a 0.45 μm microporous membrane, and then twice through a 0.22 μm microporous membrane.

[0027] 3. After the medicinal solution is qualified, fill 5.0mL of the above medicinal solution into a 5mL single-dose packaging plastic container in a grade A environment, and seal it to obtain the finished product.

Embodiment 2

[0029] formula:

[0030]

[0031] Preparation Process:

[0032] 1. Accurately weigh 1.00g of midazoribine, add 300mL of water for injection to dissolve it, and obtain solution ① for later use.

[0033]2. Accurately weigh 0.05g of chlorhexidine acetate, 7.20g of sodium dihydrogen phosphate, 0.95g of disodium hydrogen phosphate, and 4.79g of sodium chloride, add 200mL of water for injection to dissolve, stir and mix evenly to obtain a solution② spare.

[0034] 3. Mix solution ① and solution ②, stir evenly, and dilute to 1000mL with water for injection to obtain a medicinal solution.

[0035] 4. Filter the above medicinal solution once through a 0.45 μm microporous membrane, and then twice through a 0.22 μm microporous membrane.

[0036] 5. After the medicinal solution is qualified, fill 5.0mL of the above medicinal solution into a 5mL single-dose packaging plastic container in a grade A environment, and seal it to obtain the finished product.

Embodiment 3

[0038] formula:

[0039]

[0040] Preparation Process:

[0041] 1. Accurately weigh 1.00g midazoribine, 0.03g benzalkonium bromide, 6.40g sodium dihydrogen phosphate, 1.89g disodium hydrogen phosphate, 4.72g sodium chloride, 0.10g disodium edetate, add 200mL Dissolve in water for injection, stir evenly, and dilute to 1000mL with water for injection to obtain a medicinal solution.

[0042] 2. Filter the medicinal solution prepared above through a 0.45 μm microporous membrane once, and then through a 0.22 μm microporous membrane once.

[0043] 3. The filtered liquid medicine is sterilized at 121° C. for 8 minutes by autoclaving, and then cooled.

[0044] 4. After the medicinal solution is qualified, fill 5.0mL of the above medicinal solution into a 5mL single-dose packaging plastic container in a Class A environment, and seal it to obtain the finished product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an eye drop for treating eye dryness. The pH value of the eye drop is 5.0-7.0, the eye drop comprises effective components of 5-hydroxy-1-beta-D-furanose-1H-imidazole-5-carboxamide, and specifically the eye drop consists of the following components in percentage by weight: 0.05-0.1% of 5-hydroxy-1-beta-D-furanose-1H-imidazole-5-carboxamide, a proper amount of a pH value adjusting agent, 0.01-3% of an iso-osmotic agent, 0.003-0.5% of a bacteriostatic agent, 0.001-0.5% of a stabilizer, 0.01-0.5% of a tackifier, 2-5% of a solubilizer and the balance of water. Through partial treatment of the eye drop, epithelial barrier functions of dry eye mouse cornea can be protected, the number of goblet cells of cornea can be recovered, and relatively good anti-inflammatory and immunity inhibition effects can be achieved.

Description

technical field [0001] The invention belongs to the technical field of dry eye treatment, and in particular relates to an eye drop for treating dry eye. Background technique [0002] Dry eye is a common and frequently-occurring disease in ophthalmology clinics. According to the large sample dry eye epidemiological survey conducted in the United States by Schaumberg et al.: the prevalence of dry eye in women under the age of 50 is 5.7%, and the prevalence rate rises to 9.8% after the age of 75, and the dry eye of women Symptoms are more obvious than men, and the higher the education level, the higher the prevalence rate; similarly, the prevalence rate of dry eye in men aged 50-54 is 3.9%, and the prevalence rate increases to 7.67%, it is estimated that by 2030, there will be 2.79 million male dry eye patients in the United States. In my country, according to the epidemiological survey results conducted by Shi Changhong et al., among the 31,124 patients included, the prevale...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/08A61K47/02A61K47/18A61K47/10A61K47/36A61K47/26A61K47/04A61K31/7056A61P27/02
CPCA61K47/02A61K47/10A61K47/183A61K47/186A61K47/26A61K47/36A61K9/0048A61K9/08A61K31/7056A61P27/04A61K47/24
Inventor 刘祖国张晓博林祥
Owner EYE MEDICAL XIAMEN BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com